Current state of spinal muscular atrophy in Canada: Practical considerations for clinicians | Webinar report
In partnership with Muscular Dystrophy Canada (MDC), NMD4C delivered its first webinar on April 21, 2020. The topic was the current state of spinal muscular atrophy (SMA) in Canada, with a target audience of neurologists, scientists, physicians, medical trainees/students, and other allied healthcare professionals involved in the care of patients with neuromuscular disease (NMD). The goal was to share knowledge on best practices, current issues, disease diagnosis and management, and possible therapeutic interventions.
Read the webinar report HERE
Topics and speakers:
SMA Clinical Care in the Era of COVID-19
Dr. Jodi Warman Chardon (NMD4C Steering Committee member)
Newborn Screening in Ontario
Dr. Kristin Kernohan, Dr. Alex Mackenzie, Dr. Hugh McMillan (NMD4C Investigator)
Update on Zolgensma for Canada
Dr. Hugh McMillan (NMD4C Investigator)
Update on Risdiplam for Canada
Dr. Craig Campbell (NMD4C Investigator)
Adult Outcome Measures
Dr. Colleen O’Connell
Update on CNDR-SMA Project
Dr. Lawrence Korngut (NMD4C Investigator), Dr. Victoria Hodgkinson (NMD4C Collaborator)
Read next...
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.
MICYRN Secures $20 Million Grant from CIHR for a Pediatric Rare Disease Clinical Trials and Treatment Network
The NMD4C are excited to share that MICYRN’s success in securing a $20 million grant from CIHR Institute of Genetics to support the development and execution of RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network.